Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsNeurological immune reconstitution inflammatory response: riding the tide of immune recoveryDrug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyCerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyPML-IRIS during Fingolimod Diagnosed after Natalizumab DiscontinuationImmune reconstitution inflammatory syndrome in HIV-infected patientsCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisNatalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.Immune reconstitution inflammatory syndrome associated with biologic therapy.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.MRI pattern in asymptomatic natalizumab-associated PML.Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.
P2860
Q26780412-AC9E9A49-0278-4CF7-8DE6-D7108F3251E6Q27009769-86DFB75F-AE68-4384-8F53-37337D462AAEQ28082309-C8C47ED8-6B2E-4F43-9529-F60B6E184DFBQ30815289-9BC0786F-9CA6-4374-9487-58A2C66E7772Q31123447-E1504400-73FF-43A0-9DC0-AEE08BBBD6D3Q34324861-11673125-6BB8-410B-886B-62527FD7B113Q34650456-FA7FC979-C296-4938-A484-F3B687885AE3Q35100818-022C01EE-1C1F-4FE3-8613-E7B467C1640BQ36352813-7F135C00-CA9A-4B7B-838A-632B5CDBB9E6Q36484448-57AB00E8-77C6-4A6F-9FAD-210868090E0EQ36767522-25C6F9BD-8E66-4AD8-A5ED-A9813B0E2E39Q38287572-05AA5117-BA59-4713-A44B-5B873EB37AD6Q41002593-E1A5245E-22FC-4EF6-BAB8-3BF3EC3F8818Q41745436-2BEF7240-4C3B-4374-B183-C031BA818DEEQ42219711-654C83E0-A597-4661-87AC-E436B93129DAQ42226607-E065D559-A963-42C6-9161-53C5BD85772AQ46861949-B78A3DDE-8C4C-46E2-924B-B5649176FF7DQ49906338-835757E4-B89A-4A4D-A1A6-3A74BB0F37C6Q50079049-E9315584-D9EA-43F8-9DCE-847883ACAE7D
P2860
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@en
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@nl
type
label
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@en
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@nl
prefLabel
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@en
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@nl
P2093
P2860
P356
P1433
P1476
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
@en
P2093
Alfred Sorbello
Andrew J Fine
Linda Scarazzini
P2860
P304
P356
10.1002/ANA.24051
P50
P577
2014-01-01T00:00:00Z